Mette Deleuran

Mette Deleuran

Auto-generated profile, based on publicly available information

Mette Deleuran

Department of Dermatology Aarhus University Hospital and Aarhus University Aarhus Denmark

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
MDMette Deleuran
Mette Deleuran
DTDiamant Thaçi
Diamant Thaçi
LBLisa A. Beck
Lisa A. Beck
MBMarjolein de Bruin-Weller
Marjolein de Bruin-Weller
ABAndrew Blauvelt
Andrew Blauvelt
MAMarius Ardeleanu
Marius Ardeleanu
Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). To assess the long-term safety and efficacy of dupilumab in patients with AD. This ongoing, multicenter, open-label extension study (NCT01949311) evaluated long-term dupilumab treatment in adults who had previously participated in phase 1 through 3 clinical trials of dupilumab for AD. This analysis examined patients given 300 mg dupilumab weekly for up to 76 weeks at data cutoff (April 2016). Safety was the primary outcome; efficacy was also evaluated. Of 1491 enrolled patients (1042.9 patient-years), 92.9% were receiving treatment at cutoff. The safety profile was consistent with previously reported trials (420.4 adverse events/100 patient-years and 8.5 serious adverse events/100 patient-years), with no new safety signals; common adverse events included nasopharyngitis, conjunctivitis, and injection-site reactions. Sustained improvement was seen up to 76 weeks in all efficacy outcomes, including measures of skin inflammation, pruritus, and quality of life. Lack of control arm, limited number of patients with 76 weeks or longer of treatment (median follow-up, 24 weeks), and patients not receiving the approved dose regimen of 300 mg every 2 weeks. The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe AD.

1 November 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
HAH. Alexander
H. Alexander
Amy PallerAmy Paller
Amy Paller
CTC. Traidl‐Hoffmann
C. Traidl‐Hoffmann
LBL.A. Beck
L.A. Beck
ABA. De Benedetto
A. De Benedetto
CFC. Flohr
C. Flohr
Patients with atopic dermatitis (AD) have an increased risk of bacterial skin infections that cause significant morbidity and, if untreated, may become systemic. Staphylococcus aureus (S. aureus) colonizes the skin of most AD subjects and is the most common organism to cause infections. Overt bacterial infection is easily recognised by the appearance of weeping lesions, honey‐coloured crusts, and pustules. However, the wide variability in clinical presentation of bacterial infection in AD and the inherent features of AD – cutaneous erythema and warmth, oozing associated with oedema, and regional lymphadenopathy – overlap with those of infection, making clinical diagnosis challenging. Furthermore, some features may be masked because of anatomical site‐ and skin‐type‐specific features, and the high frequency of S. aureus colonization in AD makes positive skin swab culture of suspected infection unreliable as a diagnostic tool. The host mechanisms and microbial virulence factors that underlie S. aureus colonization and infection in AD are incompletely understood. The aim of this article is to present the latest evidence from animal and human studies, including recent microbiome research, to define the clinical features of bacterial infections in AD, and to summarize our current understanding of the host and bacterial factors that influence microbial colonization and virulence.

7 May 2019 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
LELawrence F. Eichenfield
Lawrence F. Eichenfield
TBThomas Bieber
Thomas Bieber
LBLisa A. Beck
Lisa A. Beck
ESEric L. Simpson
Eric L. Simpson
DTDiamant Thaçi
Diamant Thaçi
MAMarius Ardeleanu
Marius Ardeleanu
Background Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. Objective The aim was to determine the impact of dupilumab on infection rates in patients with moderate-to-severe AD. Methods This analysis pooled data from seven randomized, placebo-controlled dupilumab trials in adults with moderate-to-severe AD. Exposure-adjusted analyses assessed infection rates. Results Of 2932 patients, 1091 received placebo, 1095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 2 weeks. Treatment groups had similar infection rates overall per 100 patient-years (placebo, 155; dupilumab weekly, 150; dupilumab every 2 weeks, 156; dupilumab combined, 152), and similar non-skin infection rates. Serious/severe infections were reduced with dupilumab (risk ratio 0.43; p < 0.05), as were bacterial and other non-herpetic skin infections (risk ratio 0.44; p < 0.001). Although herpesviral infection rates overall were slightly higher with dupilumab than placebo, clinically important herpesviral infections (eczema herpeticum, herpes zoster) were less common with dupilumab (risk ratio 0.31; p < 0.01). Systemic anti-infective medication use was lower with dupilumab. Conclusions Dupilumab is associated with reduced risk of serious/severe infections and non-herpetic skin infections and does not increase overall infection rates versus placebo in patients with moderate-to-severe AD. ClinicalTrials.gov Identifiers NCT01548404, NCT02210780, NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649.

1 December 2015 in The American Journal of Medicine
Verified
Journal Article
Closed access
KHKasper Fjellhaugen Hjuler
Kasper Fjellhaugen Hjuler
MBMorten Böttcher
Morten Böttcher
CVChristian Vestergaard
Christian Vestergaard
MDMette Deleuran
Mette Deleuran
LRLine Raaby
Line Raaby
KKKnud Kragballe
Knud Kragballe

2 May 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
AWAndreas Wollenberg
Andreas Wollenberg
MKM. Kinberger
M. Kinberger
BAB. Arents
B. Arents
NAN. Aszodi
N. Aszodi
SBSebastien Barbarot
Sebastien Barbarot
CFC. Flohr
C. Flohr
The evidence‐ and consensus‐based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice. This paper summarizes the results of the second update. Twenty‐eight experts (including clinicians and patient representatives) from 12 European countries participated. The updated guideline provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib). Additionally, the updated guidelines address considerations for paediatric, adolescent, pregnant and breastfeeding patients. For all other aspects, please refer to the 2022 version.

1 August 2024 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
LBLisa A. Beck
Lisa A. Beck
RBRobert Bissonnette
Robert Bissonnette
MDMette Deleuran
Mette Deleuran
TNTakeshi Nakahara
Takeshi Nakahara
RGRyszard Galus
Ryszard Galus
ASArsalan Shabbir
Arsalan Shabbir
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent eczematous lesions and sustained pruritus.1 Due to its chronic and recurrent nature, patients with moderate to severe AD usually require long-term treatment. However, many available AD treatments, including high-potency topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), systemic corticosteroids (SCSs), systemic immunosuppressants, and UV therapy, are typically not recommended for long-term use due to concerns around safety or lack of efficacy data.2 Janus kinase inhibitors, which are also approved to treat moderate to severe AD, carry an increased risk of infections and cardiovascular events.3